The role of VEGF in triple-negative breast cancer: Where do we go from here?

Annals of Oncology

Volumn 20, Issue 10, 2009, Pages 1615-1617

  Dent, S F ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; AZD 2281; BEVACIZUMAB; BRCA1 PROTEIN; BSI 201; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PENTOSYLTRANSFERASE INHIBITOR; PROGESTERONE RECEPTOR; SUNITINIB; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

BREAST CANCER; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DNA MICROARRAY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EDITORIAL; GENE EXPRESSION; HUMAN; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; SURVIVAL TIME;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349633252     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp410     Document Type: Editorial

References (23)

1. Rakha EA, El-Sayed ME, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109(1): 25-32.
2. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer. Clin Cancer Res 2007; 13(15): 4429-4434.
3. Stockmans G, Deraedt K, Wildiers H et al. Triple-negative breast cancer. Curr Opin Oncol 2008; 20: 614-620.
4. Dolle JM, Daling JR, White E et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009; 18(4): 1157-1166.
5. Schneider BP, Winer EP, Foulkes WD et al. Triple-negative breast cancer. Clin Cancer Res 2008; 14(24): 8010-8018.
6. Kassam F, Enright K, Dent R et al. Survival outcomes for patients with metastatic triple-negative breast cancer: Implications for clinical practice and trial design. Clin Breast Cancer 2009; 9(1): 29-33.
7. Carey L, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J Am Med Assoc 2006; 295(21): 2492-2502.
8. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.
9. Diaz LK, Cryns VL, Symmans F, Sneige N. Tripe negative breast carcinoma and the basal phenotype: From expression profiling to clinical practice. Adv Anat Pathol 2007; 14(6): 419-430.
10. Yamamoto Y, Toi M, Kondo S et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996; 2: 821-826.
11. Adams J, Carder PJ, Downey S et al. Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000; 60: 2898-2905.
12. Foekens JA, Peters HA, Grebenchtchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 61: 5407-5414.
13. Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtiö J, Lewensohn R. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple negative breast cancer. Ann Oncol 2009: doi:10.1093/annonc/mdp062.
14. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
15. U.S. National Institutes of Health. BEATRICE study: A study of Avastin (bevacizumab) adjuvant therapy in triple negative breast cancer. 2009; http://clinicaltrials.gov/ct2/show/NCT00528567?term=BEATRICE&rank=1 (8 July 2009, date last accessed).
16. Yu K, Toral-Barza L, Discafani C et al. mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249-258.
17. Noh WC, Mondesire WH, Peng J et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004; 10: 1013-1023.
18. Majumder PK, Febbo PG, Bikoff R et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-601.
19. U.S. National Institutes of Health. Trial of RAD001 in triple negative metastatic breast cancer. 2009; http://clinicaltrials.gov/ct2/show/ NCT00827567?term=phase+II+RAD-001+triple+negative&cond=breast+ cancer&rank=1 (13 July 2009, date last accessed).
20. Mulcahy N. PARP inhibitors represent new direction in cancer treatment. Medscape Medical News June 25 2009. 2009; http://www.medscape.com/ viewarticle/704990 (14 July 2009, date last accessed).
21. BiPar Sciences Inc. Home page. 2009; http://www.biparsciences.com/ (14 July 2009, date last accessed).
22. O'Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 2009; 27(18s): (Abstr 3).
23. Tutt A, Robson M, Garber JE et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009; 27(18s): (Abstr CRA501).